A randomized clinical trial conducted in Denmark indicated that increasing plasma potassium levels to the high-normal range can significantly reduce adverse outcomes in patients with implantable cardioverter-defibrillators (ICDs). Over approximately 40 months, patients who had their potassium levels targeted between 4.5 and 5.0 mmol/L demonstrated a lower incidence of severe episodes such as ventricular tachycardia, hospitalizations for heart issues, and mortality compared to standard care. Safety assessment showed no treatment-related deaths, although potential risks included hospitalizations related to electrolyte imbalances.

Source: The New England Journal of Medicine